Linked Life Data

7567309

Source:http://linkedlifedata.com/resource/pubmed/id/7567309

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7567309rdf:typepubmed:Citationlld:pubmed
pubmed-article:7567309lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:7567309lifeskim:mentionsumls-concept:C0680022lld:lifeskim
pubmed-article:7567309lifeskim:mentionsumls-concept:C0031350lld:lifeskim
pubmed-article:7567309lifeskim:mentionsumls-concept:C0036689lld:lifeskim
pubmed-article:7567309lifeskim:mentionsumls-concept:C0030840lld:lifeskim
pubmed-article:7567309lifeskim:mentionsumls-concept:C0055014lld:lifeskim
pubmed-article:7567309lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:7567309lifeskim:mentionsumls-concept:C1512888lld:lifeskim
pubmed-article:7567309pubmed:issue7 Suppllld:pubmed
pubmed-article:7567309pubmed:dateCreated1995-11-22lld:pubmed
pubmed-article:7567309pubmed:abstractTextThe efficacy and safety of a 10-day course of ceftibuten oral suspension (9 mg/kg once daily) were compared with those of penicillin V (25 mg/kg/day in 3 divided doses) in children 3 to 18 years old treated for symptomatic pharyngitis and scarlet fever caused by group A beta-hemolytic streptococci (Streptococcus pyogenes). The study was prospective, randomized, multicenter and investigator-blinded; patients were randomized in a 2:1 ratio (ceftibuten:penicillin V). Overall clinical success (cure/improvement) at the primary end point of treatment (5 to 7 days posttherapy) was achieved in 97% (285 of 294) of ceftibuten-treated patients vs. 89% (117 of 132) of penicillin V-treated patients (P < 0.01). Elimination of infecting streptococci 5 to 7 days posttherapy was achieved in 91% (267 of 294) of ceftibuten-treated patients vs 80% (105 of 132) of penicillin V-treated patients (P < 0.01). A significant rise in anti-streptolysin O or anti-DNase B was observed in approximately 30% of patients in both treatment groups. No patient developed rheumatic fever or nephritis. Treatment-related adverse events were similar between the two groups; mild vomiting (2%) was most frequently reported. These data suggest that once daily ceftibuten is as safe as and more effective than three times daily penicillin V for the treatment of group A beta-hemolytic streptococcal pharyngitis.lld:pubmed
pubmed-article:7567309pubmed:languageenglld:pubmed
pubmed-article:7567309pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7567309pubmed:citationSubsetIMlld:pubmed
pubmed-article:7567309pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7567309pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7567309pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7567309pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7567309pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7567309pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7567309pubmed:statusMEDLINElld:pubmed
pubmed-article:7567309pubmed:monthJullld:pubmed
pubmed-article:7567309pubmed:issn0891-3668lld:pubmed
pubmed-article:7567309pubmed:authorpubmed-author:RodriguezWWlld:pubmed
pubmed-article:7567309pubmed:authorpubmed-author:GoldfarbJJlld:pubmed
pubmed-article:7567309pubmed:authorpubmed-author:GoochW MWM3rdlld:pubmed
pubmed-article:7567309pubmed:authorpubmed-author:PichicheroM...lld:pubmed
pubmed-article:7567309pubmed:authorpubmed-author:ReidenbergB...lld:pubmed
pubmed-article:7567309pubmed:authorpubmed-author:MclinnS ESElld:pubmed
pubmed-article:7567309pubmed:issnTypePrintlld:pubmed
pubmed-article:7567309pubmed:volume14lld:pubmed
pubmed-article:7567309pubmed:ownerNLMlld:pubmed
pubmed-article:7567309pubmed:authorsCompleteYlld:pubmed
pubmed-article:7567309pubmed:paginationS102-7lld:pubmed
pubmed-article:7567309pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:meshHeadingpubmed-meshheading:7567309-...lld:pubmed
pubmed-article:7567309pubmed:year1995lld:pubmed
pubmed-article:7567309pubmed:articleTitleCeftibuten vs. penicillin V in group A beta-hemolytic streptococcal pharyngitis. Members of the Ceftibuten Pharyngitis International Study Group.lld:pubmed
pubmed-article:7567309pubmed:affiliationUniversity of Rochester Medical Center, NY 14642, USA.lld:pubmed
pubmed-article:7567309pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7567309pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:7567309pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:7567309pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:7567309pubmed:publicationTypeMulticenter Studylld:pubmed